Infants with hemodynamically significant congenital heart disease are eligible for RSV prophylaxis if they are younger than what age?

• A. <6 months
• B. <18 months
• C. <12 months
• D. <24 months

Answer: (C)

Palivizumab RSV prophylaxis is targeted to infants with hemodynamically significant congenital heart disease and is limited to those in the first year of life. The accepted age cutoff is younger than 12 months at the start of the RSV season because the greatest benefit—and the strongest evidence for reducing hospitalization—occurs in the first year. Once an infant reaches 12 months (or older), routine prophylaxis for HS-CHD during RSV season is not typically indicated. So the correct criterion is being under 12 months old.